IMMUNOBIOLOGY Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma Running head: ANTITUMOR ACTIVITY OF NEW RITUXIMAB VARIANTS
نویسندگان
چکیده
International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai 200433, People’s Republic of China; National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai 201203, People’s Republic of China School of Medicine and School of Pharmacy, The Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, 227 South Chongqing Road, Shanghai 200025, People’s Republic of China B.L. and L.Z. contributed equally to this work. Corresponding author: Yajun Guo, International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, People’s Republic of China. Phone: 86-21-81870801; Fax: 86-21-65306667; e-mail: yjguo@smmu.edu.cn Blood First Edition Paper, prepublished online October 14, 2009; DOI 10.1182/blood-2009-06-225474
منابع مشابه
LYMPHOID NEOPLASIA Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma
1International Joint Cancer Institute and 301 General Hospital Cancer Center, Second Military Medical University, Shanghai; 2National Engineering Research Center for Antibody Medicine and Shanghai Key Laboratory of Cell Engineering & Antibody, Shanghai; and 3School of Medicine and School of Pharmacy, Center for Antibody Medicine of Ministry of Education, Shanghai Jiao Tong University, Shanghai,...
متن کاملCharacterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
Despite widespread use of the anti-CD20 monoclonal antibody (mAb), rituximab, in treating B-cell lymphomas, its efficacy remains variable and often modest. A better understanding of rituximab-mediated killing mechanisms is essential to develop more effective therapeutic agents. In this study, we modulated the binding property of rituximab by introducing several point mutations in its complement...
متن کاملPotent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Despite major advances in the treatment of non-Hodgkin lymphoma (NHL), including the use of chemotherapeutic agents and the anti-CD20 antibody rituximab, the majority of patients eventually relapse, and salvage treatments with non-cross-resistant compounds are needed to further improve patient survival. Here, we evaluated the antitumor effects of the microtubule destabilizing agent monomethyl a...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کاملDevelopment of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...
متن کامل